DUBLIN--(BUSINESS WIRE)--The "Top 10 Cancer Drugs Market by Region: Opportunity Analysis and Industry Forecast, 2018-2026" report has been added to ResearchAndMarkets.com's offering.
The global top 10 cancer drugs sales was valued at $63,619 million in 2018 and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026.
Cancer is a medical condition in which abnormal cells grow with the potential to invade or spread to other parts of the body. Different forms of the drugs used for the treatment of cancer majorly include, chemotherapy, targeted therapy, immunotherapy, and others.
Increase in prevalence of various forms of cancer, increase in popularity of advance therapies such as biological & targeted drug therapies, and rise in geriatric population worldwide are the key factors that drive the growth of the global cancer drugs market. Furthermore, rise in cancer awareness, increase in R&D activities, and availability of cancer drugs are expected to boost the market growth.
However, the high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.
List of key players profiled in the report:
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson (Janssen Global Services, LLC,)
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Revlimid occupied 15.22% share of the global top 10 cancer drugs sales in 2018.
- Keytruda is anticipated to grow at the highest rate during the analysis period.
- The Europe cancer drugs accounted for 21.21% share of the global top 50 cancer drugs sales in 2018.
- The top 10 cancer drugs accounted for 52.96% share of the global top 50 cancer drugs sales in 2018.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA
In the current scope of the study, Europe was the leading revenue contributor to the market in 2018, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR from 2019 to 2026, owing to increase in adoption of advanced therapies, surge in research, development, & innovation activities; and rise in awareness related to different cancers.
Key Topics Covered:
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
2. Executive Summary
2.1. Key Findings Of The Study
2.2. CXO Perspective
3. Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Top Player Positioning, 2018
3.4. Porter's Five Forces Analysis
3.5. Market Dynamics
220.127.116.11. Rise In Incidence Of Cancer Across The Globe
18.104.22.168. Surge In Global Geriatric Population
22.214.171.124. Increase In Government Expenditure On Healthcare
126.96.36.199. Adverse Effects Associated With The Use Cancer Drugs
188.8.131.52. High Growth Potential In Untapped Emerging Economies
184.108.40.206. Increase In Number Of Pipeline Drugs
3.5.4. Impact Analysis
4. Cancer Drugs Market, By Region
4.1.1. Global Sales Of Top 50 Anticancer Drugs
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Country
220.127.116.11. Russia Cancer Drugs Market
18.104.22.168.1. Russia Sales Of Top 10 Cancer Drugs
22.214.171.124. Netherlands Cancer Drugs Market
126.96.36.199. Switzerland Cancer Drugs Market
188.8.131.52. Sweden Cancer Drugs Market
184.108.40.206. Belgium Cancer Drugs Market
220.127.116.11. Austria Cancer Drugs Market
18.104.22.168. Norway Cancer Drugs Market
22.214.171.124. Denmark Cancer Drugs Market
126.96.36.199. Poland Cancer Drugs Market
188.8.131.52. Finland Cancer Drugs Market
184.108.40.206. Portugal Cancer Drugs Market
220.127.116.11. Greece Cancer Drugs Market
18.104.22.168. Ireland Cancer Drugs Market
22.214.171.124. Czech Republic Cancer Drugs Market
126.96.36.199. Hungary Cancer Drugs Market
188.8.131.52. Romania Cancer Drugs Market
184.108.40.206. Ukraine Cancer Drugs Market
5. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/w7lp3g